International practice of corticosteroid replacement therapy in congenital adrenal hyperplasia - data from the I-CAH registry
- Bacila, I.
- Freeman, N.
- Daniel, E.
- Sandrk, M.
- Bryce, J.
- Ali, S.R.
- Yavas Abalı, Z.
- Atapattu, N.
- Bachega, T.A.
- Balsamo, A.
- Birkebæk, N.
- Blankenstein, O.
- Bonfig, W.
- Cools, M.
- Costa, E.C.
- Darendeliler, F.
- Einaudi, S.
- Elsedfy, H.H.
- Finken, M.
- Gevers, E.
- Claahsen-van der Grinten, H.L.
- Guran, T.
- Güven, A.
- Hannema, S.E.
- Higham, C.E.
- Iotova, V.
- van der Kamp, H.J.
- Korbonits, M.
- Krone, R.E.
- Lichiardopol, C.
- Luczay, A.
- Mendonca, B.B.
- Milenkovic, T.
- Miranda, M.C.
- Mohnike, K.
- Neumann, U.
- Ortolano, R.
- Poyrazoglu, S.
- Thankamony, A.
- Tomlinson, J.W.
- Vieites, A.
- de Vries, L.
- Ahmed, S.F.
- Ross, R.J.
- Krone, N.P.
DOIAbstract
Objective: Despite published guidelines no unified approach to hormone replacement in congenital adrenal hyperplasia (CAH) exists. We aimed to explore geographical and temporal variations in the treatment with glucocorticoids and mineralocorticoids in CAH. Design: This retrospective multi-center study, including 31 centers (16 countries), analyzed data from the International-CAH Registry. Methods: Data was collected from 461 patients aged 0-18 years with classic 21-hydroxylase deficiency (54.9% females) under follow-up between 1982 – 2018. Type, dose and timing of glucocorticoid and mineralocorticoid replacement was analyzed from 4174 patient visits. Results: The most frequently used glucocorticoid was hydrocortisone (8...
Add to ORKG